MedDataX Logo

Treatment of Patients With Anxiety Disorder (0777-022)

NCT ID: NCT00539578

Last Updated: 2015-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

270 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Study Completion Date

2003-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

NCT00703833

Generalized Anxiety Disorder
COMPLETED PHASE2

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

NCT00546624

Anxiety Disorder
COMPLETED PHASE2

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

NCT00543920

Anxiety Disorders
COMPLETED PHASE2

Experimental Medication For the Treatment of Generalized Anxiety Disorder

NCT00097708

Anxiety Disorder
COMPLETED PHASE3

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

NCT00108836

Anxiety Disorders
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Generalized Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0777

Duration of Treatment: 4 weeks

Intervention Type DRUG

Comparator: placebo (unspecified)

Duration of Treatment: 4 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and Female patients ages 18 to 70

Exclusion Criteria

* Women who are breastfeeding or pregnant
* Positive result at prestudy on urine drug screen for illicit drugs
* History of alcohol or drug abuse
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MK0777-022

Identifier Type: -

Identifier Source: secondary_id

2007_622

Identifier Type: -

Identifier Source: secondary_id

0777-022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
NCT04598867 UNKNOWN PHASE3
Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder
NCT00397098 TERMINATED PHASE3
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236067 COMPLETED PHASE3
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
NCT00266747 COMPLETED PHASE3
Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)
NCT05565352 ENROLLING_BY_INVITATION
Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
NCT02218736 COMPLETED PHASE2
А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
NCT04524975 COMPLETED PHASE2
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
NCT00658372 TERMINATED PHASE3
An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder
NCT00374166 COMPLETED PHASE2
Tailored Internet-administrated Treatment of Panic Symptoms - A Randomised Controlled Trial
NCT01296321 UNKNOWN NA
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236015 COMPLETED PHASE3
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
NCT00106860 COMPLETED PHASE3
6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
NCT00738738 WITHDRAWN PHASE3
Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder
NCT05772104 RECRUITING PHASE3
Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder
NCT07330648 RECRUITING PHASE2
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
NCT00390533 COMPLETED PHASE3
Identifying Decision Making Parameters in Healthy Volunteers and Anxiety Patients
NCT05092971 COMPLETED NA
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236054 COMPLETED PHASE3
The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers
NCT01826786 COMPLETED PHASE1
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
NCT00735267 TERMINATED PHASE3
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder
NCT00535340 TERMINATED PHASE3
A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
NCT00677352 COMPLETED PHASE4
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
NCT02305797 COMPLETED PHASE3
Combined Treatment for Generalized Anxiety Disorder (GAD)
NCT00620776 COMPLETED PHASE2
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
NCT00731120 COMPLETED PHASE3